Vigil Neuroscience’s Upcoming Presentation at Healthcare Conference
Vigil Neuroscience, Inc. (Nasdaq: VIGL) from Watertown is making significant advancements in biotechnology, especially in the treatment of neurodegenerative diseases. The company is looking forward to participating in an engaging fireside chat at the Cantor Global Healthcare Conference, set for Thursday, September 19, 2024. During this event, management will share insights on the future of treatments in this essential healthcare field.
Webcast Registration Information
If you're keen to hear Vigil's insights and strategies, the registration for the live webcast is currently open. This allows a wider audience to partake in the session online, aligning with the company’s mission and vision. After the live discussion, there's an option to view an archived version of the webcast on the company’s website for 90 days, ensuring those who miss the live event still have a chance to catch up.
About Vigil Neuroscience
Vigil Neuroscience is dedicated to creating innovative treatments for both rare and common neurodegenerative diseases. The company is well-regarded for its groundbreaking method of restoring microglial vigilance—these immune cells in the brain play a crucial role in maintaining neural health. Vigil utilizes advanced neuroscience drug development techniques to formulate precision therapies designed to improve the quality of life for patients and their families.
Key Products and Research
The standout clinical candidate for the company is Iluzanebart, a fully human monoclonal antibody agonist. This drug is aimed specifically at the triggering receptor expressed on myeloid cells 2 (TREM2), focusing on patients diagnosed with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). ALSP is a rare and severe neurodegenerative condition.
Alongside Iluzanebart, Vigil Neuroscience is also developing VG-3927, a new small molecule that acts as a TREM2 agonist. VG-3927 primarily targets common neurodegenerative diseases resulting from microglial dysfunction, with an initial emphasis on Alzheimer's disease. This dual-pronged approach underscores Vigil's commitment to addressing both rare and widespread disorders within the neurodegenerative landscape.
Staying Informed with Vigil Neuroscience
In today’s fast-paced digital environment, having easy access to information is crucial for investors and healthcare enthusiasts. Vigil Neuroscience regularly shares important updates and key information on its official website, particularly in the “Investors” section. Stakeholders are encouraged to frequently check this area for the most recent insights and updates, ensuring they're well-informed about the company’s progress.
Investor and Media Contacts
As Vigil continues its journey of innovation and engagement with the scientific community and prospective investors, communication plays a vital role. Those interested in investment-related inquiries can contact Leah Gibson, the Vice President of Investor Relations and Corporate Communications, at lgibson@vigilneuro.com. Additionally, media-related questions can be directed to Megan McGrath from CTD Comms at megan@ctdcomms.com.
Frequently Asked Questions
What is the main focus of Vigil Neuroscience?
Vigil Neuroscience is primarily dedicated to developing innovative treatments for neurodegenerative diseases by harnessing the unique attributes of microglia.
When will Vigil present at the healthcare conference?
Vigil Neuroscience is scheduled to present at the Cantor Global Healthcare Conference on September 19, 2024.
How can I access the webcast of the presentation?
You can register for the live webcast on Vigil's official website, or catch the archived version available for 90 days after the event.
What are Vigil's key products?
Vigil's key products include Iluzanebart, focused on a rare neurodegenerative disease, and VG-3927, which is aimed at treating more common diseases like Alzheimer’s.
Who should I contact for more information?
For inquiries related to investors, reach out to Leah Gibson, and for media inquiries, you can contact Megan McGrath.
